UPSHER-SMITH EXPANDS VIGADRONE® (VIGABATRIN) FRANCHISE TO INCLUDE TABLETS
MAPLE GROVE, Minn., July 31, 2023 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the recent launch of VIGADRONE® (vigabatrin) Tablets, USP 500 mg, a fully substitutable, AB-rated generic version of Sabril® (vigabatrin) Tablets, 500 mg.* The Company also offers VIGADRONE® (vigabatrin) for Oral Solution, USP 500 mg.
- Please see Important Safety Information, including Boxed Warning for Risk of Permanent Vision Loss at the end of this communication.
- All people who take VIGADRONE:
You are at risk for permanent vision loss with any amount of VIGADRONE. - Your risk of vision loss may be higher the more VIGADRONE you take daily and the longer you take it.
- The most common side effects of VIGADRONE in adults include: blurred vision, sleepiness, dizziness, problems walking or feeling uncoordinated, shaking (tremor) and tiredness.